Oncology Highlights - February 2019
The Human Tumor Atlas Network (HTAN), barcoding single cells, FDA&EMA approvals, M&A oncology in February
Oncology Highlights - January 2019
Overriding the "don't eat me" signal, AI test predicts aggresive cancer, Lilly buys Loxo, FDA, EMA approvals and more
Oncology Highlights - December 2018
2018 year in review, mining the gold-DNA interactions, skin cells armored to fight cancer, IO market news, FDA's real world evidence program
Oncology Highlights - November 2018
Bacterial "robot-factoriees", fat fueled attenuation of NK cells, 2018 ESMO IO awards, FDA and EMA approvals and more...
Oncology Highlights - October 2018
Markers that reveal resistance to IO, a novel way to block TGF-B, M&A in oncology, Galien awards and more
The growing challenge of handling multistream data capture in clinical trials - ACDM 2019
This year's annual conference of the Association for Clinical Data Management (ACDM) took place in Amsterdam. During a two-day event, the emphasis was on the growing challenges of multistream data capture in clinical trials, wi...
SMS-oncology sets out to improve patient recruitment for clinical trials
Drug development crucially relies on accurately designed and well recruiting clinical trials. However, low accrual rates of clinical trials and unmet recruitment targets have been global attention points for many years. A 70-80...
EMA & FDA Anti-cancer Drugs Recommendations for Approval in 2018
In 2018, EMA and FDA made a total of 44 positive recommendations for anti-cancer medicines to receive marketing approval.
ESMO 2018: Immunotherapy and other stories
ESMO 2018: Immunotherapy and other stories The annual European Society for Medical Oncology (ESMO) 2018 Congress took place from 19-23 October 2018 in breathtaking Munich, Germany. Held under the tagline "Securing access to op...
Combination immunotherapy: The latest revolution in cancer treatment
An analysis of the clinical landscape The present focus in the treatment of cancer is immunotherapy, in particular immunotherapies that are trialed in a combination regimen. By combining immuno-oncology (IO) agents with oth...